Knowing now matters.™ Alere delivers reliable and actionable information through rapid diagnostic tests, resulting in better clinical and economic healthcare outcomes globally. Alere is headquartered in Waltham, Massachusetts.

Company Growth (employees)
Type
Public
HQ
Waltham, US
Founded
1981
Size (employees)
9,700 (est)+6%
Website
alere.com
Alere was founded in 1981 and is headquartered in Waltham, US

Alere Office Locations

Alere has an office in Waltham
Waltham, US (HQ)
200 51 Sawyer Rd

Alere Data and Metrics

Alere Financial Metrics

Alere's revenue was reported to be $588.2 m in Q1, 2017
USD

Revenue (Q1, 2017)

588.2 m

Net income (Q1, 2017)

(64.1 m)

EBIT (Q1, 2017)

(5 m)

Market capitalization (18-Aug-2017)

4.3 b

Cash (31-Mar-2017)

601.5 m
Alere's current market capitalization is $4.3 b.
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

3 b2.6 b2.5 b582.3 m

Revenue growth, %

(15%)(5%)(76%)

Gross profit

1.5 b1.2 b1.1 b

Gross profit Margin, %

50%47%45%

Sales and marketing expense

102 m

R&D expense

31.4 m

General and administrative expense

148.5 m

Operating expense total

281.9 m

EBIT

134.8 m93.4 m137.9 m(16 m)

EBIT margin, %

4%4%6%(3%)

Income tax expense

(46.3 m)66.7 m(52.7 m)(50.8 m)

Net Income

(70.3 m)9.9 m206.8 m15.7 m
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Revenue

737.9 m736.2 m608.2 m629.2 m602 m578.2 m611.1 m582.4 m588.2 m

Sales and marketing expense

150.7 m136.3 m109.1 m107.2 m106.5 m99.8 m102.5 m102 m94.2 m

R&D expense

37.4 m38.7 m28 m27.2 m36 m27.1 m28.4 m31.4 m26.3 m

General and administrative expense

159.9 m130.2 m92.7 m60.8 m101.3 m115 m128.4 m129.3 m166.3 m

Operating expense total

348 m305.2 m229.8 m195.2 m243.8 m241.8 m259.3 m262.7 m286.7 m

EBIT

(8.8 m)37.6 m27.4 m91.8 m29.2 m28.2 m22.5 m3.4 m(5 m)

EBIT margin, %

(1%)5%5%15%5%5%4%1%(1%)

Income tax expense

(6.6 m)76.6 m(8.8 m)17.7 m(18.9 m)(208 k)3.1 m(50.9 m)18.6 m

Net Income

(55.7 m)(142.2 m)209.2 m229.5 m235 m(10 m)(44.9 m)(22.8 m)(64.1 m)
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

361.9 m378.5 m502.2 m567.2 m

Inventories

129.7 m131.6 m152.2 m308.9 m

Current Assets

1.5 b1.8 b1.5 b1.5 b

PP&E

545.2 m456.8 m446 m441.2 m

Goodwill

3.1 b2.9 b2.8 b2.8 b

Total Assets

7.1 b6.7 b6 b5.6 b

Accounts Payable

187.4 m213.6 m195.8 m195.9 m

Total Debt

3.8 b3.6 b2.9 b2.9 b

Current Liabilities

673.2 m743.8 m724.5 m676.2 m

Non-Current Liabilities

4.3 b4 b3.2 b3.1 b

Total Liabilities

5 b4.8 b3.9 b

Additional Paid-in Capital

3.3 b3.4 b3.4 b3.5 b

Retained Earnings

(1.6 b)(1.6 b)(1.5 b)(1.6 b)

Total Equity

2.1 b2 b2.1 b1.8 b

Debt to Equity Ratio

1.8 x1.8 x1.4 x1.6 x

Debt to Assets Ratio

0.5 x0.5 x0.5 x0.5 x

Financial Leverage

3.4 x3.4 x2.9 x3.1 x
USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Cash

464.9 m479.4 m490.7 m506.2 m566.2 m601.5 m

Inventories

366.3 m362.2 m350.9 m333.8 m348.8 m322.5 m

Current Assets

1.9 b1.9 b1.5 b1.4 b1.5 b1.5 b

PP&E

448.3 m445.3 m445.2 m438.8 m446.3 m439.8 m

Goodwill

2.9 b2.8 b2.8 b2.8 b2.8 b2.8 b

Total Assets

6.7 b6.6 b5.9 b5.8 b5.9 b5.7 b

Accounts Payable

186.9 m194.2 m165.8 m194.2 m211.5 m211.4 m

Current Liabilities

1.1 b1.1 b678.9 m561.9 m706.5 m713.3 m

Non-Current Liabilities

3.4 b3.3 b3.1 b3.2 b3.1 b3.1 b

Additional Paid-in Capital

3.4 b3.4 b3.5 b3.5 b3.5 b3.5 b

Retained Earnings

(1.5 b)(1.4 b)(1.5 b)(1.5 b)(1.5 b)(1.7 b)

Total Equity

2.2 b2.1 b2.1 b2 b2.1 b1.8 b

Financial Leverage

3.1 x3.1 x2.8 x2.9 x2.9 x3.1 x
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(70.3 m)9.9 m206.8 m(137.3 m)

Depreciation and Amortization

439.4 m335.8 m309.3 m285.6 m

Accounts Receivable

(36 m)1.3 m(14 m)26.7 m

Inventories

(12 m)(48 m)(43 m)

Accounts Payable

13 m47.9 m(10.8 m)4.4 m

Cash From Operating Activities

244.8 m233.8 m207.3 m179.3 m

Purchases of PP&E

(122.2 m)(102.9 m)(90.8 m)(67.7 m)

Cash From Investing Activities

(258.3 m)(59.5 m)537.5 m2.6 m

Long-term Borrowings

(471.5 m)(65.1 m)(2.7 b)(198.3 m)

Cash From Financing Activities

49 m(118.2 m)(633 m)(109.8 m)
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(55.7 m)(142.2 m)209.2 m229.5 m235 m(10 m)(44.9 m)(22.8 m)(64.1 m)

Depreciation and Amortization

196 m290.8 m74.4 m147 m233.5 m72.5 m142.4 m214.2 m60.9 m

Accounts Receivable

13.2 m20.4 m(16.9 m)(27.5 m)(11.3 m)(9.2 m)20 m22.1 m33.1 m

Accounts Payable

30.8 m38.3 m(18.6 m)(23.3 m)(16 m)(31.5 m)(1 k)18.5 m13.4 m

Cash From Operating Activities

125.2 m216.9 m28.4 m32.5 m137.3 m(4.6 m)94.1 m147 m61.1 m

Purchases of PP&E

(54.4 m)(80.5 m)(25.6 m)(47.3 m)(67.9 m)(14.5 m)(32.3 m)(50 m)(10.4 m)

Cash From Investing Activities

(51.2 m)(69.3 m)557.2 m132.4 m36.3 m2.8 m(13.6 m)11.3 m(14.7 m)

Long-term Borrowings

(32.2 m)(48.1 m)(463 m)(2.1 b)(2.1 b)(17.3 m)(177.6 m)(187.8 m)(10.2 m)

Cash From Financing Activities

(38.8 m)(55.2 m)(566.7 m)(100.2 m)(87.3 m)(12.5 m)(73.6 m)(99.1 m)(21.5 m)
USDY, 2017

Revenue/Employee

62.2 k

Financial Leverage

3.1 x

Alere Market Value History

Alere Median Salaries

Source: 23 public H-1B filings from Alere

Traffic Overview of Alere

Alere Online and Social Media Presence

Alere News and Updates

Abbott Labs Has Officially Moved to Kill Its Deal to Buy Alere

But Alere says that none of the arguments made by Abbott give it grounds to abandon the merger.

Deal Professor: In Abbott’s Bid to Halt Purchase of Alere, the MAC Makes a Comeback

Delaware courts have been tough to convince on material adverse change clauses, but this is one deal where the buyer might very well prevail.

Breakingviews: Abbott’s Sale of Eye Surgery Unit Should Ease Its Merger Woes

Wrapping up deals with Alere and St. Jude has troubled Abbott Laboratories; a cash infusion will come at a welcome time.

Morning Agenda: Female Lawyers Challenge Gender Bias, Potential for Banking Mergers, Abbot and Alere Point Fingers and a Silicon Dream Collapses

Female lawyers are increasingly pushing back when they think their employers are favoring men and penalizing women.

In the Almost Marriage of Abbott and Alere, Both Sides Point Fingers

Alere Says Abbott has buyer’s remorse; Abbott says Alere stalled on obtaining key regulatory approvals to close the transaction.

Abbott’s No Good, Very Bad M&A Week

Abbott is acquiring Alere, which makes medical tests, and St. Jude Medical, which makes cardiovascular devices. The deals have been hampered by inquiries into sales practices and concerns over some devices being vulnerable to cyberattacks.
Show more

Alere Company Life and Culture

You may also be interested in